Oruka Therapeutics’ (ORKA) “Buy” Rating Reiterated at BTIG Research

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating reaffirmed by equities researchers at BTIG Research in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $151.00 price objective on the stock. BTIG Research’s price target points to a potential upside of 43.62% from the company’s current price.

Several other research firms have also weighed in on ORKA. Wall Street Zen raised Oruka Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Leerink Partners set a $120.00 target price on shares of Oruka Therapeutics in a report on Thursday, April 30th. HC Wainwright reaffirmed a “buy” rating and set a $120.00 price target on shares of Oruka Therapeutics in a report on Monday, August 3rd. Barclays upped their price objective on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a research report on Monday, April 27th. Finally, UBS Group raised their target price on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $134.30.

Oruka Therapeutics Price Performance

Shares of ORKA opened at $105.14 on Tuesday. Oruka Therapeutics has a one year low of $12.84 and a one year high of $105.31. The company has a market cap of $6.34 billion, a P/E ratio of -54.20 and a beta of -0.34. The firm has a 50 day simple moving average of $83.59 and a two-hundred day simple moving average of $60.75.

Oruka Therapeutics (NASDAQ:ORKA) last issued its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). On average, analysts expect that Oruka Therapeutics will post -2.06 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Joana Goncalves sold 7,947 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $69.28, for a total value of $550,568.16. Following the sale, the insider directly owned 32,718 shares in the company, valued at $2,266,703.04. This represents a 19.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Carl Dambkowski sold 105,000 shares of the company’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $58.97, for a total transaction of $6,191,850.00. Following the completion of the sale, the director directly owned 73,743 shares in the company, valued at approximately $4,348,624.71. This represents a 58.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 188,406 shares of company stock valued at $12,019,683 over the last 90 days. 23.49% of the stock is owned by corporate insiders.

Institutional Trading of Oruka Therapeutics

Several hedge funds have recently modified their holdings of the stock. Moody Aldrich Partners LLC bought a new position in shares of Oruka Therapeutics during the 4th quarter worth about $3,844,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Oruka Therapeutics during the first quarter worth about $1,811,000. SG Americas Securities LLC bought a new stake in Oruka Therapeutics during the fourth quarter worth $251,000. Perceptive Advisors LLC boosted its stake in shares of Oruka Therapeutics by 16.4% in the 4th quarter. Perceptive Advisors LLC now owns 1,476,501 shares of the company’s stock worth $44,753,000 after buying an additional 208,480 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in Oruka Therapeutics by 18.3% during the first quarter. The Manufacturers Life Insurance Company now owns 72,563 shares of the company’s stock worth $3,559,000 after buying an additional 11,205 shares during the last quarter. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.